September 10, 2018

Investigational Therapy TAK-659 Targets Lymphomas Linked to Epstein-Barr Virus, Mouse Study Shows

News

TAK-659, an investigational compound being developed by Takeda Pharmaceuticals, is able to target lymphomas associated with Epstein-Barr virus (EBV) infection, preventing their growth and spread, a mouse study shows. The ... Read more

June 23, 2015August 23, 2016

Novel Drug Shows Promising Results In Lymphoma Treatment

News

During the 13th International Conference on Malignant Lymphoma, held this June in Lugano, Switzerland, promising results were presented relative to a new drug TAK-659, an inhibitor of spleen tyrosine kinase (SYK) with ... Read more